In the present study, we hypothesized that a quantitative increase in CD163+ tumor-associated macrophages (TAMs) in pT2-stage seminoma compared to pT1 may represent a clinically relevant factor, reflecting a shift toward an immunosuppressive tumor microenvironment at a more advanced stage of disease progression. The gene discussed is CD163; the disease is seminoma.